Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children.

Herbert NG. and Goulder PJR., (2023), Curr Opin HIV AIDS, 18, 229 - 236

Hepatitis B Virus Prevalence and Mother-to-Child Transmission Risk in an HIV Early Intervention Cohort in KwaZulu-Natal, South Africa.

Millar J. et al, (2023), Open Forum Infect Dis, 10

Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile.

Nguyen AN. et al, (2023), Pediatr Res

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.

Johnson SA. et al, (2023), Clin Exp Immunol, 212, 249 - 261

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.

Huo J. et al, (2023), Cell Rep, 42

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209

Paediatric HIV slow-progression is associated with early CD8+ T-cell PD-1 expression and a stem-like phenotype.

Adriano Vieira V. et al, (2023), JCI Insight

Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents.

Jay C. et al, (2023), Front Immunol, 14

Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members.

Jay C. et al, (2023), Front Immunol, 14

Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion.

Jay C. et al, (2023), Front Immunol, 14

Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope.

Dolton G. et al, (2022), Cell, 185, 2936 - 2951.e19

Next-generation point-of-care testing in pediatric human immunodeficiency virus infection facilitates diagnosis and monitoring of treatment

Bengu N. et al, (2022), Medicine (United States), 101

Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence.

Fernández-Luis S. et al, (2022), BMC Public Health, 22

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV)

Khan K. et al, (2022), Clinical Infectious Diseases, 75, E857 - E864

Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and with Human Immunodeficiency Virus on Antiretroviral Therapy during the First South African Infection Wave

Snyman J. et al, (2022), Clinical Infectious Diseases, 75, E249 - E256

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.

Sampson O. et al, (2022), J Immunol Methods, 504

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), JCI Insight, 7

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A. et al, (2022), Nat Commun, 13

Load More

1
2
3
4
5
6
7
...
»